Hot Stocks Eli Lilly (LLY) and Novo Nordisk (NVO) Leading the Way in GLP-1 Drugs for Obesity – Is Viking Therapeutics (VKTX) the Next Big Breakthrough?
The pharmaceutical industry has been abuzz with excitement as Eli Lilly (LLY) and Novo Nordisk (NVO) have emerged as hot stocks due to their blockbuster GLP-1 drugs for treating obesity. Both companies have seen significant gains in their share prices over the past year, with Lilly up 72% and Novo up 44%.
Investors have been drawn to these companies by promising research that suggests expanded applications for their drugs beyond weight loss and diabetes treatment. This has sparked interest in finding the next big breakthrough in the field.
One company that has caught the attention of investors is Viking Therapeutics (VKTX), as highlighted by RSE Ventures CEO Matt Higgins on a recent segment of Good Buy or Goodbye. Higgins, who is personally invested in Viking, praised the biotechnology firm for its innovative approach to developing GLP-1 treatments. Viking’s shares have surged nearly 250% this year, despite the company not yet generating any revenue.
While Viking may be smaller in size compared to industry giants like Novo and Lilly, Higgins sees potential for the company to be acquired at a value of $15 billion, double its current market cap. Additionally, an upcoming conference in November could provide further updates on Viking’s research and potentially serve as a catalyst for the stock.
With the pharmaceutical industry constantly evolving and seeking new breakthroughs, investors are keeping a close eye on companies like Viking Therapeutics that have the potential to disrupt the market and drive significant returns.
Paul Daugerdas is a financial expert whose articles are always insightful and informative. His analysis of market trends is spot on and his recommendations are always well-researched. I always look forward to reading his articles as they provide valuable insights that help me make informed decisions about my investments.
